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Abstract Tissue factor pathway inhibitor-alpha (TFPI-α) is a Kunitz-type serine protease inhibitor,
which suppresses coagulation by inhibiting the tissue factor (TF)/factor VIIa complex as
well as factor Xa. In static plasma-phospholipid systems, TFPI-α thus suppresses both
factor Xa and thrombin generation. In this article, we used a microfluidics approach to
investigate how TFPI-α regulates fibrin clot formation in platelet thrombi at low wall
shear rate. We therefore hypothesized that the anticoagulant effect of TFPI-α in plasma
is a function of the local procoagulant strength—defined as the magnitude of thrombin
generation under flow, due to local activities of TF/factor VIIa and factor Xa. To test this
hypothesis, we modulated local coagulation by microspot coating of flow channels
with 0 to 100 pM TF/collagen, or by using blood from patients with haemophilia A or B.
For blood or plasma from healthy subjects, blocking of TFPI-α enhanced fibrin
formation, extending from a platelet thrombus, under flow only at <2 pM coated
TF. This enhancement was paralleled by an increased thrombin generation. For mouse
plasma, genetic deficiency inTFPI enhanced fibrin formation under flow also at 0 pM TF
microspots. On the other hand, using blood from haemophilia A or B patients, TFPI-α
antagonism markedly enhanced fibrin formation at microspots with up to 100 pM
coated TF. We conclude that, under flow, TFPI-α is capable to antagonize fibrin
formation in a manner dependent on and restricted by local TF/factor VIIa and factor
Xa activities.
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Tissue factor pathway inhibitor-α (TFPI-α) is a Kunitz-type
serine protease antagonist, known to downregulate the
extrinsic coagulation pathway by inhibiting the complexes
of tissue factor (TF), factor VIIa and factor Xa.1–4 In blood,
about 15% (0.25–0.5 nM) of the TFPI circulates in an active,
full-length form, designated as TFPI-α, while the remainder
is carboxy-terminally truncated and bound to lipopro-
teins.4,5 In addition, platelets store a pool of full-length
TFPI-α (1,200 copies/cell),6 which is slowly released upon
activation of the cells. The alternatively spliced form TFPI-β
remains immobilized at the surface of endothelial cells via a
glycophosphatidylinositol anchor.7–9 The three Kunitz
domains of TFPI-α have complementary roles in coagulation
suppression. The first domain binds and inhibits TF/factor
VIIa; the second domain inhibits factor Xa, while the third
domain regulates the binding of cofactor protein S.10–13
Furthermore, TFPI-α can interact with other components
of the coagulation system, that is, factor V and phosphati-
dylserine (PS)-containing membranes via its positively
charged C-terminus.14 From its ability to interfere with
both TF and factor Xa activity (tenase), TFPI-α is considered
to be a central player in the natural anticoagulant pathway.
The formation of a fibrin-containing thrombus involves
complex interactions between platelets and the coagulation
system.15 Exposed collagen fibres can act as a prothrombotic
surface and stimulate platelet deposition, phosphatidylserine
(PS) exposure, intrinsic coagulation pathway activation and
thrombin generation.16,17 Together with TF, collagen further-
more triggers the extrinsic coagulation pathway.18 The coa-
gulant process is further modulated by the coagulant capacity
of plasma, the local procoagulant activity providedbyplatelets
and the blood flow rate, jointly indicated here as procoagulant
strength (defined as the magnitude of thrombin generation
under flow). Earlier work has shown that, at high blood flow
and shear rate, the formation of fibrin is confined to the
immediate environment of a thrombus with PS-exposing
platelets, whereas at low shear/flow rate such as in veins the
formed fibrin fibres progressively extend into the lumen.19–21
Anchoring of the fibrin fibres at ‘fibrin-coated’ platelets
appeared to rely on PS exposure, integrin αIIbβ3 epitopes,
and factor XIIIa-mediated transglutaminase activity.22,23
At a low procoagulant strength, such as with low factor
VIII or IX levels (haemophilia A or B), and concordant low
intrinsic tenase activity, TF/collagen-induced platelet activa-
tion and fibrin formation under flow are greatly impaired,24
thus pointing to potent interactions of TF-triggered and
intrinsic tenase-enhanced thrombin generation via PS-
exposing platelets. Given the critical role of both TF/factor
VIIa and factor Xa activities in providing the thrombin-
generating activity required for fibrin clot formation, a
relevant question now is how the anticoagulant protein
TFPI-α interferes in this process. So far, the role of TFPI has
not been investigated in this setting.
Mice with homozygous deficiency in TFPI (Tfpi/) die in
utero from disseminated intravascular coagulation, but part
of the offspring survives when combined with low TF
expression or absence of the platelet receptor PAR4
(F2rl3/).25,26 This phenotype suggests the existence of a
balanced procoagulant–anticoagulant triggering, for exam-
ple, by TF and TFPI, in normal clot formation. Under static
conditions in vitro, this indeed has been examined.27 How-
ever, howTPFI exerts control at physiologicalflowconditions
in these mouse models is largely unclear.
In this article, we investigated the suppressive role of
plasma TFPI-α on fibrin clot formation under conditions of
high and low procoagulant strength under flow by changing
the local TF concentration or lowering the intrinsic tenase
activity using blood from haemophiliac patients. Collec-
tively, our data indicate that in normal blood or plasma
TFPI-α, effects are confined to low TF levels. However, at




Bovine serum albumin (BSA) was purchased from MP Bio-
medicals (Illkirch, France). Fluorogenic thrombin substrate
Z-Gly-Gly-Arg-7-amino-4-methylcoumarin HCl (Z-GGR-
AMC) was obtained from Bachem (Bubendorf, Switzerland).
Recombinant human full length TFPI-α (TFPIfl, amino acids 1-
276) was a kind gift from Dr. W. Buurman (Maastricht, the
Netherlands). Monoclonal antibodies against the Kunitz-1,
Kunitz-2, Kunitz-3, or C-terminus domains of human TFPI-α
were purchased from Sanquin (Amsterdam, the Nether-
lands), and were mixed in a 1:1:1:1 ratio. Recombinant TF
(Innovin) was from Siemens (Marburg, Germany). Corn
trypsin inhibitor was from Haematologic Technologies
(Essex Junction, Vermont, United States). Monoclonal anti-
body against factor VIIa (200 µg/mL), polyclonal antibodies
against TF (CD142) (1 mg/mL) and corresponding irrelevant
antibodies of same Ig type were purchased from American
Diagnostica (Stamford, Connecticut, United States). DiOC6
was from AnaSpec (Waddinxveen, the Netherlands); Alexa
Fluor (AF) 647-labeled human fibrinogen from Invitrogen
(Carlsbad, California, United States); Horm type I collagen
from Nycomed Pharma (Munich, Germany). Congenital fac-
tor VIII–deficient plasma (citrate-anticoagulated) was
obtained from George King Bio-Medical (Overland Park,
Kansas, United States). Other materials were from Sigma
Aldrich (Zwijndrecht, the Netherlands).
Human Blood Collection and Plasma Preparation
Human blood was obtained after medical ethical approval
from healthy volunteers and patients, after full informed
consent, according to the declaration of Helsinki. Blood
donorswere free from antithromboticmedication for at least
2 weeks. Two patients were included with haemophilia A
(factor VIII activity 2% and <1%, the latter with 3.8 BU factor
VIII inhibitor), and two patients with haemophilia B (factor
IX activity 5 and 7%). Patients had not obtained treatment
with coagulation factors for at least 2 weeks.
Collection of blood was by venipuncture of the median
cubital vein into 1/10 volume of 3.2% trisodium citrate, with
Thrombosis and Haemostasis Vol. 118 No. 3/2018






























40 μg/mL corn trypsin inhibitor (CTI) added as appropriate.
To prepare pooled normal platelet-free plasma, citrate antic-
oagulated bloodwas centrifuged twice for 10 minutes at 250
g. Platelet-free plasma from 23 healthy donors was pooled,
aliquoted, snap frozen and stored at 80°C, as described.28
Plasma samples were treated with antibodies or isotype-
matched IgG to inhibit specified coagulation factors (typi-
cally 30 µg/mL, incubated at 37°C for 5minutes). Considering
that TFPI-α is the main or only active form of TFPI in human
plasma,4,5 we termed blood or plasma samples treated with
antibody mixture (anti Kunitz-1, Kunitz-2, Kunitz-3 and C-
terminal domains of TFPI) as TFPI-α inhibited.
Mouse Blood Collection and Plasma Preparation
Animal experiments were approved by local animal ethics
committees.Miceheterozygous for the TFPI-null allele (back-
crossed on C57Bl/6 background for 10 generations) were
mated with PAR4-deficient mice (F2rl3/) to produce dou-
bly heterozygous mice, as described before.26 Subsequent
cross-breeding resulted in Tfpiþ/þ F2rl3/, Tfpiþ/ F2rl3/
and Tfpi/ F2rl3/ mice at C57Bl/6 background.26 Blood
from wild-type (C57Bl/6) or genetically transformed mice
was collected into 3.2% citrate (10:1 ratio) and 50 µg/mL CTI;
blood samples were immediately used to prepare platelet-
free plasma by double centrifugation, and then frozen at
80°C until use.26 For thrombus formation, wild-type C57Bl/
6 mouse blood was collected into 3.2% citrate, and used for
whole blood flow perfusion measurements, as described.24
Preparation of Thrombogenic Surfaces for Flow
Perfusion
Cleaned glass coverslips were coated with three consecutive
microspots of Horm type I collagen, by applying 2 μL of 50 μg/
mL collagen type I (centre-to-centre distance: 3mm).29After
rinsing with saline and drying under nitrogen gas, aliquots of
2.0 µL TF (Innovin, concentrations as indicated) or control
solution were applied on each microspot. For experiments
with human blood, collagen/TF-coated coverslips were
blocked for 1 hour with 5% BSA in Hepes buffer pH 7.45
(136 mM NaCl, 10 mM Hepes, 2.7 mM KCl, 2 mM MgCl2, 1
mg/mL glucose). Assuming homogeneous TF distribution, a
coating with 2.0 μL of 1, 2, 10, 20 or 100 pM (microspots of
6.75mm2) gave a calculated applied TF density of 0.2, 0.4, 1.8,
3.6 or 17.8  106 molecules TF per mm2, respectively. Col-
lagen was coated at a density of 14.8 ng/mm2. For experi-
ments with mouse blood, coverslips were coated similarly,
but blocked with BSA-containing modified Tyrode’s buffer
pH 7.45 (136 mM NaCl, 5 mM Hepes, 2.7 mM KCl, 0.42 mM
NaH2PO4, 2 mM MgCl2, 1 mg/mL glucose).
Assessment of Thrombus and Fibrin Formation under
Flow
To allow human thrombus formation, citrate anticoagulated
blood was perfused through a parallel-plate flow chamber
with collagen/TF microspots at a wall shear rate of 1,000 s1
for 4.0 minutes, similarly as described.19,30 The microspot
with lowest TF amount was proximal in the flow chamber. In
the two-step procedure, platelet thrombiwere formed on the
microspots, after which plasma samples (pretreated as
required) were perfused over the thrombi at indicated shear
rate.19 Plasma samples were recalcified immediately prior to
flow. Fibrin formation was assessed by brightfield micro-
scopy using a 40  /1.4 numerical aperture oil immersion
objective and 2 post-magnification.30 Fluorescent labels
(DiOC6 and AF647-fibrinogen) were added to blood and
plasma, respectively, as appropriate.
From representative parts of the microspots, brightfield
and fluorescence images were recorded during flow in real
time at a frequency of 0.2 to 1.0 Hz. Digital brightfield images
were assessed off-line for the presence of multi-pixel fibrin
fibres, radially extending from preformed platelet thrombi.
For precise determination of the time to first fibrin forma-
tion,31 series of subtraction images were created using
scripts written in Fiji/ImageJ (version 1.48g: Rasband, NIH,
Bethesda, Maryland, United States). For measurement of
fluorescent fibrin formation, fluorescence images were ana-
lysed for fibrillar structures.21 An off-set was applied for the
presence of platelet-bound fibrinogen, using reference
images with blocked coagulation. ►Supplementary Fig. S1
(online only) shows image overlays for the detection of fibrin
fibres obtained with both methods.
For experiments with mouse blood and plasma, a similar
two-step procedure was followed. In brief, platelet thrombi
were formed on 0 to 10 pM TF/collagen microspots by
perfusion of wild-type C57Bl/6 blood supplemented with
DiOC6 (0.5 µg/mL) at 1,000 s1, followed by a 1-minute rinse
with modified Tyrode’s buffer (5 mM Hepes, 136 mM NaCl,
2.7 mM KCl, 0.42 mM, NaH2PO4, 2 mM MgCl2, 1 mg/mL
glucose and 0.1% BSA, pH 7.45). Subsequently, plasma sam-
ples (40 µL) from indicated mice were supplemented with
AF647-fibrinogen (17.3 μg/mL), recalcified and immediately
perfused over the preformed thrombi at 150 s1 to allow
clotting. Image capturing in real time and analysis were
performed as described previously.
For the one-step procedure with human blood, coagula-
tionwas introduced by co-perfusion of 0.1 vol. recalcification
buffer (Hepes buffer pH 7.45 containing 63.2 mM CaCl2 and
31.5 mMMgCl2) at 1,000 s1 and, after 4.0minutes, switch to
the desired wall shear rate. Blood samples were pre-labeled
with AF647-fibrinogen (17.3 μg/mL) and DiOC6 (0.5 µg/mL,
staining platelets). Brightfield contrast and confocal fluores-
cence images were recorded with a camera-containing line-
scanning Live-7 microscopic system (Carl Zeiss, Oberkochen,
Germany) and a 63  /1.4 numerical aperture oil immersion
objective.32 Time series of images were recorded at a fre-
quency of 0.2 to 1.0 Hz, and analysed off-line, as described
earlier.
Real-Time Thrombin Generation in Flow Chambers
To measure thrombin generation at thrombus-containing
microspots, fluorogenic thrombin substrate Z-GGR-AMC
(0.5 mM) was added to blood samples, and fluorescence
accumulationwasmeasured in real time.33 In short, thrombi
were generated as described earlier, after which blood flow
was stopped and fluorescence images were recorded at
0.03 Hz at excitation and emission wavelengths of
Thrombosis and Haemostasis Vol. 118 No. 3/2018






























357  44 nm and 447  60 nm, respectively. Sample illu-
mination was discontinued between captures of images to
prevent bleaching.
Thrombin Generation in Plasma
In citrated human (patient) plasmas, thrombin generation
was measured by calibrated automated thrombinography.
Reactionmixtures (125 µL) contained 80 µL plasma, towhich
were added indicated amounts of TF (0–15 pM, f.c.), 16 mM
CaCl2, 30 µM phospholipids and 0.32 mM fluorogenic
thrombin substrate. Plasma samples were pre-treated with
anti-TFPI antibodies, as indicated. Thrombin peak height (in
nM) was plotted against the TF concentration. Assays were
run in triplicate. In constructed TF dose–response curves, the
thrombin peak height is known to saturate at lower levels
when using pooled plasmas from male donors than those
from female donors.34 Hence, for an adequate comparison
with the male haemophilia patients, in this study we used
controlled reference plasmas obtained from male donors.
Statistical Analysis
Data are presented asmeans  SEM. Significance ofdifference
between conditions was determined with a nonparametric
Mann–Whitney U-test, using the statistical package for social
sciences (SPSS 11.0). p-Values <0.05 were considered statis-
tically significant. The program GraphPad Prism 6.0 (San
Diego, California, United States) was used for graphics.
Results
Moderate Anticoagulant Role of Human Plasma TFPI-α
in Fibrin Formation from Platelet Thrombi under Flow
To study the anticoagulant potential of TFPI-α under phy-
siological flow conditions as a function of the local TF
density, microfluidic chambers were used, containing three
microspots of collagen with increasing amounts of TF in the
flow direction. Initial experiments were performed using
microspots (2 μL applied, spreading over about 6.75 mm2)
coated with 50 μg/mL collagen-I and 0, 2 or 10 pM TF
(corresponding to coated densities of 14.8 ng collagen/
mm2 and 0, 0.4 or 1.8  106 molecules TF/mm2). In a two-
step approach, initially platelet thrombi were formed on the
microspots by 4-minute perfusion of citrate-anticoagulated
whole blood (from healthy donors, collected in the presence
of corn trypsin inhibitor to prevent activation of the contact
system). Brightfield microscopy confirmed the presence of
stable thrombi consisting of multilayered (20–25% surface
area coverage) platelets on all microspots (►Fig. 1A). No
platelet deposition was observed outside of TF/collagen-
coated areas, such as described earlier.21,35 In step 2, coagu-
lation was induced by superfusion of the thrombi with
recalcified normal plasma at defined, low wall shear rate
(150 s1).
For microspots with 0 pM TF/collagen, this resulted in the
appearance of fibrin fibres starting after 595  73 seconds
(mean  SEM, n ¼ 8). Real-time image recording indicated
that the fibres were formed by radially extending from the
platelet thrombi, similarly as earlier observed for fibrin on
individual platelets. Time to first fibrin formation could be
precisely assessed by image subtraction.31 For the down-
stream microspots with 2 or 10 pM TF/collagen, fibrin clots
formed at earlier time points, that is, with first appearance of
fibres after 376  73 and 356  101 seconds, respectively
(►Fig. 1A–C).
Control experiments indicated that on microspots coated
with only 10 pM TF (no collagen), platelet deposition and
fibrin formation were absent during >10 minutes of flow,
which is in agreement with our earlier observation that
Fig. 1 TFPI-α inhibition enhances fibrin formation on platelet thrombi under flow at low TF density. Platelet thrombi were generated by
perfusion of human blood over three consecutive microspots of collagen with increasing amounts of 0, 2 and 10 pM coated TF (4 minutes at
1,000 s1). Platelet thrombi were superfused at shear rate of 150 s1 with recalcified normal plasma (vehicle or TFPIα inhibited); fibrin formation
from the platelet thrombi was determined from recorded images. Shown are representative brightfield images, captured at indicated times after
start of perfusion with vehicle-treated (A) or TFPI-α-inhibited (B) plasma (no TF, bar ¼ 25 µm). (C) Time to fibrin formation at microspots with
consecutively 0, 2 and 10 pM TF. Means  SEM, n ¼ 4–5; p < 0.05 versus vehicle; NS, not significant.
Thrombosis and Haemostasis Vol. 118 No. 3/2018






























platelets scaffold the formation of fibrin in this flowmodel.21
Supplementation of blood and plasma with blocking anti-
bodies against TF/factor VIIa resulted in a marked delay in
start of fibrin formation to >600 seconds (n ¼ 3) at all
microspots. This confirmed overall activity of the TF/factor
VIIa pathway.
To investigate the role of TFPI-α in this process, plasma
(from healthy blood donors) was preincubated with a cock-
tail of antibodies inhibiting all forms of TFPI, including the
active TFPI-α. Thrombin generation measurements con-
firmed that TFPI-α was fully blocked in the plasma samples
(see later). Flow perfusion of TFPI-inhibited plasma over
preformed thrombi (shear rate of 150 s1) resulted in a
significant shortening of the onset of fibrin formation on
microspots with 0 pM TF/collagen, that is, starting at
413  27 seconds (mean  SEM, n ¼ 4), when compared
to the lag time of 595  73 seconds for vehicle-treated
plasma (►Fig. 1B, C). Markedly, TFPI-α inhibition did not
significantly shorten the time to fibrin formation on micro-
spots with 2 or 10 pM TF/collagen (p > 0.50). This suggested
that the procoagulant strength provided by even low
amounts of immobilized TF overruled the anticoagulant
effect of TFPI-α.
Dual-colour confocal fluorescence microscopy was then
applied for precise assessment of the localization and
kinetics of fibrin formation. Platelets in the blood were
stained with a vital membrane label DiOC6 (green), while
AF647-fibrinogen (red) was added to the plasma, as a label
that effectively incorporates into fibrin clots.21 Blood perfu-
sion resulted in thrombi with DiOC6-labeled platelets, which
were similarly sized on all collagen microspots with or
without TF (►Fig. 2A). Low-shear flow with plasma did not
change the fluorescence from platelets (►Fig. 2D), while
labeled fibrin fibres started to accumulate after about
600 seconds (0 pM TF) or about 360 seconds (2 and 10 pM
TF; ►Fig. 2A, C). Dual recording of brightfield and fluores-
cence images indicated a precise overlap of fibrin fibres,
radially extending from the thrombi, in the two sets of
images (►Supplementary Fig. S1 [online only]).
The fibrin(ogen) labeling experiments confirmed that
inhibition of plasma TFPI-α shortened the onset of fibrin
formation on 0 pM TF/collagen microspots under flow with
200 seconds (►Fig. 2B). Time traces for vehicle-treated
plasma samples also showed a marked shortening of fibrin
accumulation at 2 or 10 pM TF/collagen microspots, when
compared to 0 pM TF/collagen microspots, although rates of
fibrin accumulation were similar for all microspots (►Fig.
2C). UponTFPI-α inhibition, a nomore than small shortening
of the fibrin accumulation was observed at 2 to 10 pM TF/
collagen spots, which was statistically not significant
(p ¼ 0.25). The appearance of fluorescent fibrin fibres,
extending from platelet thrombi, was not affected by inhibi-
tion of TFPI (►Supplementary Fig. S2A [online only]).
Reducing the wall shear rate during plasma perfusion
from 150 to 50 s1 gave similar results, in that for 0 TF/
collagen microspots TFPI-α inhibition prolonged the time to
fibrin formation by 63  15% with borderline significance
(n ¼ 4, p ¼ 0.06). Taken together, these experiments pointed
to an inhibiting effect of plasma TFPI-α on platelet-depen-
dent fibrin formationwhich, however, could be overruled by
local immobilized TF.
Moderate Anticoagulant Role of Mouse Plasma TFPI-α
in Fibrin Formation from Platelet Thrombi under Flow
To further underscore the role of TFPI infibrin formation at TF/
collagen surfaces, TFPI-deficient mouse plasma was used.
Since TFPI deficiency as such is lethal in mouse,36 plasmas
were used from Tfpiþ/ or Tfpi/ mice, which also lacked the
PAR4 thrombin receptor (F2rl3/) and thereby survived.26
First, platelet thrombi were generated with wild-type mouse
blood and then post-perfused at 150 s1 with plasma from
wild type or TFPI-deficient mice. For collagen microspots and
wild-type plasma, we observed a relatively fast onset of fibrin
formation (in comparison with human plasma) of 208  19
seconds (►Fig. 3A, B). Markedly, the plasmas from Tfpi/
F2rl3/mice, in comparison to those from Tfpiþ F2rl3/ and
Tfpiþ/þ F2rl3/ mice, gave a further shortening and enhance-
ment of fibrin formation (►Fig. 3A, B). Also in this mouse
system, fibrin fibres were exclusively produced from the
platelet thrombi. Thrombin generation measurements in the
knockoutplasmasconfirmedtheabsenceofTFPI activity.26We
concluded that, inmouse, the absence of plasma TFPI led to an
increased platelet-dependent fibrin formation under flow at
limited coagulant strength (noTF), thus in agreementwith the
human data.
Increased Anticoagulant Role of Plasma TFPI-α in
Fibrin Formation in Haemophilic Blood
Earlier findings using static assay systems or isolated factors
have indicated that the anticoagulant effect of TFPI can
increase under conditions of factor VIII or IX deficiency.37–39
To investigate this further, at first commercial haemophilia
plasmas were used to assess fibrin formation under flow.
Since pilot results indicated that higher TF concentrations
could be used with such plasmas, microspots were prepared
of collagenwith 0, 20 or 100 pM coated TF (corresponding to
0, 3.6 and 18  106molecules TF/mm2) in theflow direction.
For the 0 and 20 pMTFmicrospots, perfusionwith factor VIII-
deficient plasma resulted in a greatly delayed fibrin forma-
tion, which was nearly normalized with blocking antibodies
against TFPI-α but not with irrelevant control antibodies
(►Fig. 4A, B). On spots with the highest concentration of TF
(100 pM), the blocking of TFPI-αwas only limitedly effective
(►Fig. 4A, B).
Anticoagulant Role of Human TFPI-α in Single-Step,
Whole Blood Flow Tests
To substantiate these findings, we also monitored fibrin
formation in a one-step, whole blood procedure, in which
recalcified blood was directly flowed over TF/collagen
microspots (0, 1 or 10 pM coated) initially at high shear
rate (1,000 s1) to allow platelet binding, and subsequently
at low shear rate (150 s1) to stimulate fibrin formation.
With blood from control subjects, this shear rate reduction
shortened the time to fibrin formation on 0 pM TF/collagen
spots from >1,500 seconds to 880  110 seconds (n ¼ 4,
Thrombosis and Haemostasis Vol. 118 No. 3/2018






























Fig. 2 Effect of TFPI-α inhibition on kinetics of platelet-dependent fibrin formation under flow. Platelet thrombi were generated by perfusion of
DiOC6-labeled human blood over microspots with collagen and indicated amounts of TF, as for ►Fig. 1. Platelet thrombi were superfused with
recalcified normal plasma containing AF647 fibrinogen. Shown are representative confocal fluorescence images (no TF, time points indicated)
after perfusion with vehicle-treated plasma (A) or TFPI-α-inhibited plasma (B). Bars ¼ 25 µm. Time traces of fibrin formation (C) and platelet
adhesion (D) (fluorescence image analysis) at platelet thrombi for microspots with 0, 2 and 10 pM TF (n ¼ 3).
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p < 0.05). Treatment of blood with anti-TFPI antibodies
further shortened this time to <600 seconds on both 0
and 1 pM TF microspots (►Fig. 5A). On the contrary,
addition of recombinant TFPI (3.75 nM) to the blood delayed
the time to fibrin formation on all TF/collagen microspots
by about threefold (n ¼ 3, p < 0.05).
Similar studieswere then performedwith blood from two
patients with haemophilia A (2 and <1% of normal factor
VIII) and two patients with haemophilia B (5 and 7% of
normal factor IX). In comparison to blood from controls, in
blood from all patients, anti-TFPI antibody treatment mark-
edly shortened the prolonged fibrin formation on 0, 1 and 10
pM TF microspots (►Fig. 5B–E). However, on 100 pM TF
spots, the already fast onset of fibrin formation was not
further affected by antibody treatment. Interestingly, fibrin
formation curves (assessed from confocal images of fibrin
fluorescence) indicated that, in spite of the earlier onset,
anti-TFPI treatment did not affect the slope of fibrin forma-
tion, in case of haemophilia A (►Supplementary Fig. S3A, B
[online only]) or haemophilia B (►Supplementary Fig. S3C–D
[online only]), blood or with coatings of 1 or 10 pM TF. Taken
together, these results indicate that, for these patients with
relatively low intrinsic tenase capacity, blockage of TFPI-α
shortened the lag time to fibrin formation, as long as this was
not maximally shortened by the highest (100 pM) TF coating
density.
Anticoagulant Role of Plasma TFPI-α in
Platelet-Dependent Thrombin Generation
Measurement
Previous thrombin generation tests with phospholipid-con-
taining plasma demonstrated that the thrombin generation–
Fig. 3 Deficiency in murine TFPI enhances fibrin formation on platelet thrombi under flow. Wild-type murine platelet thrombi were generated
whole blood (DiOC6-labeled) perfusion over collagen microspots. Recalcified plasmas containing AF647-fibrinogen from wild type, Tfpi
þ/þ
F2rl3/, Tfpiþ/ F2rl3/ or Tfpi/ F2rl3/ mice were post-perfused at low shear rate (150 s1), while DiOC6 and AF647 fluorescence was
monitored by confocal microscopy. (A) Representative DiOC6 and AF647-fibrin images after 200 s of flow (bars ¼ 25 µm). (B) Times to first fibrin
formation per genotype, measured by image subtraction analysis. Means  SEM, n ¼ 4–5; p < 0.05 versus wild type.
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inhibiting effect of TFPI-α can extend to TF concentrations
up to 10 pM.13,40,41 This was confirmed in the current
study (►Supplementary Fig. S4A, B [online only]). Blocking
of factor XIa was without effect on the thrombin generation
profile, which pointed to a no more than small feedback role
of thrombin-activated factor XI. Thrombin generation mea-
surements with plasmas from the two haemophilia A and
two haemophilia B patients showed an almost annulled
thrombin generation peak with 1 pM TF (►Supplementary
Fig. S4B [online only]). This can be explained by the absence
of the intrinsic tenase amplification loop of thrombin gen-
eration. Using a higher concentration of 10 pM TF, thrombin
generation in the patients’ plasmas was less severely
impaired, indicating that the amplification loop is partly
circumvented. For all patient samples, TFPI-α inhibi-
tion partly antagonized the annulation of thrombin genera-
tion at 1 pM TF, while it (nearly) normalized this
process at 10 pM TF. This supports the idea that plasma
TFPI-α acts as a more potent anticoagulant at a lower
magnitude of thrombin generation (resulting in a reduced
procoagulant strength), that is, at low intrinsic tenase
activity.
In addition, we examined the effect of TFPI inhibition on
thrombin generation at thrombi formed on TF/collagen
microspots in flow chambers. Therefore, fluorescent throm-
bin substrate was added to blood and, after thrombus for-
mation, stasis was applied to allow fluorescence
accumulation.33 With control blood, inhibition of TFPI-α
moderately enhanced the cleavage of thrombin substrate,
with initial starts of thrombin generation in the same time
interval (►Fig. 6A). However, with haemophilia A blood,
TFPI-α inhibition had a stronger accelerating effect on sub-
strate cleavage (►Fig. 6B). This is in good agreement with the
enhancement of thrombin generation seen in platelet-free
haemophilia plasma samples.
Discussion
This study describes how plasmatic TFPI-α antagonizes the
process of fibrin formation onplatelet thrombi in coagulating
blood/plasma under conditions of low shear flow. With
blood or plasma from control subjects, the anticoagulant
role TFPI-α appeared to be restricted to surfaces with no
more that low TF density (i.e., coating of <2 pM TF, corre-
sponding to <0.4  106 molecules/mm2). This was con-
firmed in a mouse system by using plasmas from mice
with a genetic deficiency in TFPI. Furthermore, we found
that the anticoagulant role of TFPI-αwasmarkedly enhanced
in haemophilia patients with a deficiency in factor VIII or IX
and, hence, an impaired intrinsic tenase activity and lower
thrombin generation potential. This anticoagulant effect
detected with haemophilia blood now extended surfaces
with higher TF densities (up to 40  106 molecules/mm2).
Together, these data indicate that a prohaemostatic effect of
human TFPI-α inhibition is not restricted to static systems of
thrombin generation in plasma, but extends to conditions of
flowing whole blood and fibrin clot production from platelet
thrombi, provided that the local procoagulant strength (TF
density) is low. Our data furthermore underscore the pro-
posal that inhibition of TFPI activity can be an effective way
to normalize haemostasis in factor VIII-deficient patients.42
Different mechanisms for the action of TFPI have been
proposed beyond that of TF/factor VIIa inhibition. These
include protein S–dependent inhibition of factor
Xa,10,13,41–43 and inhibition of prothrombinase activity.12
Regardless of the relative contribution of these mechanisms,
it appears that in flowing blood the anticoagulant action of
TFPI is confined to conditions where limited amounts of TF
are present and/or the amount of factor Xa generated is
reduced. One explanation for this restricted effect of TFPI
might be ongoing accumulation of PS-exposing platelets
Fig. 4 TFPI-α inhibition restores fibrin formation of haemophiliac plasma on platelet thrombi at higher TF density. Platelet thrombi were
generated by blood perfusion over microspots with collagen and increasing amounts of 0, 20 and 100 pM coated TF. Thrombi were superfused
with indicated recalcified plasmas, and time to fibrin formation was recorded as for ►Fig. 1. (A) Perfusion with control or factor (F)VIII-deficient
plasma, and depletion of TFPI-α as indicated. (B) Perfusion with factor VIII–deficient plasma, treated with irrelevant (irr.) control antibody or anti-
TFPI antibodies. Means  SEM, n ¼ 4–7; p < 0.05 versus control plasma (A) or FVIII-deficient plasma (B).
Thrombosis and Haemostasis Vol. 118 No. 3/2018






























with high coagulant capacity.19,30 Earlier, we have shown
that these procoagulant platelets provide an active surface
for the assembly of factors VIIIa and IXa, thereby greatly
promoting intrinsic tenase activity.24Hence, in normal blood
under flow, the procoagulant strength provided by platelets
may restrict the anticoagulant actions of plasma pool of TFPI-
α. From another point of view, it can be considered that,
under conditions of flow, the enhancement of fibrin forma-
tion caused by higher densities of coated TF is already near
maximal, and thus so strong that it cannot further be
accelerated by TFPI inhibition.
Strikingly, in blood or plasmawith low levels of factor VIII
(haemophilia A patients) or factor IX (haemophilia B
patients), TFPI inhibition caused a more marked improve-
ment of fibrin formation, even at higher concentrations of
coated TF (10–100 pM). TFPI belongs to the category of slow-
tight binding coagulation inhibitors that inactivate factor Xa
molecules in a biphasic fast/slow fashion, but can be over-
ruled by high factor Xa generation.11 This may explain why
its activity is limited under conditions of high factor Xa and
thrombin generation. On the other hand, static thrombin
generation measurements indicate that, also at high TF
levels, TFPI blockage has an additional increasing effect on
thrombin peak levels by 50 to 100 nM (►Supplementary
Fig. S4 [online only]). From this perspective, it is likely
that under conditions of high thrombin generation, the
Fig. 5 TFPI-α inhibition normalizes platelet-dependent fibrin formation in haemophiliac blood. Platelet thrombi were generated by blood
perfusion over microspots of collagen with indicated concentrations of TF; blood samples were treated with vehicle or anti-TFPI antibodies. Time
to first fibrin formation was recorded per microspot during blood perfusion at 150 s1. Presented are times to fibrin formation. (A) Blood from
control subjects. (B, C) Blood from haemophilia A patients A1 (2% factor VIII) and A2 (<1% with 3.8 BU factor VIII inhibitor). (D, E) Blood from
haemophilia B patients B1 (5% factor IX) and B2 (7% factor IX). Means  SEM, n ¼ 3–4; p < 0.05 versus vehicle.
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anticoagulant activity of TFPI is insufficient to suppress
thrombin levels so much that they become limiting for the
control of fibrin formation. Taken together, this suggests
that, in an additive way, the local activities of both TF/factor
VIIa and intrinsic tenase determine the procoagulant
strength of fibrin formation at a thrombus under flow, and
accordingly the ability of TFPI-α to antagonize fibrin forma-
tion relies on both the TF/factor VIIa and tenase activities. In
support of this suggestion, others have also proposed that
blood flow can control coagulation onset via a positive
feedback loop of TF/factor VIIa and factor Xa activities.44
Already in 1991, it was proposed that inhibition of TFPI
activity can reverse the low clotting potential of blood from
haemophilic patients.37–39 Later studies have supported this
effect in whole blood or plasma assays with a variety of TFPI-
α inhibitors, albeit under stasis. Using thromboelastography
and thrombin generation assays, it was shown that the anti-
TFPI aptamer BAX499 can partly restore coagulation in case
of factor VIII deficiency.45 Under stasis, the same aptamer
was found to improve fibrin formation in the setting of low
coagulation.27 Also in rabbits, TFPI inhibition has been
shown to shorten bleeding times.46,47
In addition to TFPI, also the Kunitz domain containing
amyloid-beta A4 protein (protease nexin II)48 has been identi-
fied in the human platelet proteome.6 In the experiments,
however, we did not obtain evidence for a consistent role of
platelet-derived anticoagulants on the kinetics of fibrin for-
mation under the present flow conditions. In future studies,
however, it is worth to reinvestigate this in more detail.
Taken together, our data indicate that, under venous, low-
shear flow conditions, TFPI-α suppresses platelet-dependent
fibrin formation most actively under conditions of low TF
density and intrinsic tenase activity, that is, at low procoa-
gulant strength. Thesefindings thereby provide novel insight
into the possibilities and limitations of TFPI antagonism to
normalize haemostasis in haemophilia patients.
What is known about this topic?
• Tissue factor pathway inhibitor-α (TFPI-α) in plasma
inhibits TF and factor Xa.
• Antagonism of TFPI-α effectively normalizes impaired
thrombin generation in haemophiliac plasmas.
• Both TF and intrinsic tenase activity (factors VIII and
IX) support fibrin generation at thrombi under flow
conditions.
What does this paper add?
• In flowed normal blood or plasma, TFPI-α antagonism
enhances platelet-dependent fibrin formation only at
low TF density.
• In flowed haemophilia A or B blood, providing reduced
coagulant strength, TFPI-α is a stronger anticoagulant
even at high TF density.
• Deficiency of mouse TFPI enhances fibrin formation
under flow at low TF density.
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Fig. 6 Effect of TFPI-α inhibition on whole blood thrombin generation on platelet thrombi under stasis. Thrombi with procoagulant platelets
were generated by whole blood perfusion over 10 pM TF/collagen microspots. Blood samples were pretreated with vehicle or anti-TFPI
antibodies, and supplemented with Z-GGR-AMC (0.5 mM). After 4 minutes, the fluorescence accumulation of cleaved thrombin substrate was
recorded under stasis to assess for thrombin generation. Shown are representative thrombin generation curves with blood from control subjects
(A) or haemophilia A patients (B). Means  SEM (n ¼ 3), p < 0.05 versus vehicle.
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